ASCO 2010: Stellenwert von Sunitinib und Temsirolimus bestätigt mRCC-Patienten profitieren vonLangzeittherapie mit Sunitinib

Publisher: Karger

E-ISSN: 2296-5262|33|8-9|483-483

ISSN: 2296-5270

Source: Oncology Research and Treatment, Vol.33, Iss.8-9, 2010-09, pp. : 483-483

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next